Inclusion Criteria:~1. Mild Cognitive Impairment (MCI) or dementia due to Alzheimer's disease (AD)~2. Biomarker
criteria:~ Cerebral Spinal Fluid (CSF) Amyloid Beta 1-42 (AÎ²42) ≤ 600 pg/mL, or A ratio of total tau to AÎ²42
≥ 0.39.~3. Mini-Mental State Exam (MMSE) ≥ 20~4. Blood laboratories, urinalysis, and electrocardiogram are
within normal limits or deemed clinically not significant by the site investigator~5. Stable medications
(including approved AD therapies) for at least 4 weeks~6. At least 6 years of education~7. Able to swallow oral
tablets~8. Speaks English fluently~9. Available qualified study partner (≥3 times per week in-person
communication with the participant)~
